Imatinib Qilu (Imatinib)

Imatinib blocks the activity of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases by binding to their ATP‑binding pockets. This prevents phosphorylation of downstream proteins, halting the signaling cascades that drive uncontrolled proliferation of leukemic and stromal tumor cells.

The dose of Imatinib Qilu is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Prescribers determine the appropriate regimen and adjust it as needed during therapy.

Imatinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used during pregnancy only when the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may harm the infant.

To order Imatinib Qilu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and GIST. Newer agents such as dasatinib or nilotinib have higher potency and may be used in cases of resistance or intolerance, but they can have different safety profiles. Choice of therapy depends on disease characteristics, prior treatment, and patient tolerance.

Imatinib Qilu should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Imatinib is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their healthcare provider. Swallow the tablet whole; do not crush or chew unless directed otherwise.

Serious adverse events include hepatotoxicity, cardiotoxicity (such as reduced left‑ventricular ejection fraction), severe neutropenia, thrombocytopenia, pulmonary hypertension, and rare cases of anaphylaxis. Patients should be monitored regularly for liver function, cardiac status and blood counts to detect these risks early.

Imatinib is contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should be avoided in pregnant women unless absolutely necessary, in patients with severe hepatic impairment, and in those with uncontrolled cardiac disease. Clinicians must assess each patient’s medical history before initiating therapy.